IPHA
Innate Pharma S.A.
$1.50
+0.00%
2026-10-23
About Innate Pharma S.A.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Key Fundamentals
EPS (TTM)
€-0.56
ROE
-271.4%
Revenue Growth (YoY)
16.5%
Profit Margin
0.0%
Debt/Equity
525.45
Beta
0.88
Market Cap
$189.9M
Avg Volume (10D)
73K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$2.71
60D Low
$1.41
Avg Volume
169K
Latest Close
$1.50
Get breakout alerts for IPHA
Sign up for Breakout Scanner to receive daily notifications when IPHA triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Innate Pharma S.A. (IPHA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IPHA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IPHA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.